ClinicalTrials.gg
TerminatedNCT01116102INFUSE-AT1AUpdated Oct 24, 2011Results posted

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

A Phase 4 interventional study of Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution in Dehydration, sponsored by Baxter Healthcare Corporation. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-24.

Sponsored by Baxter Healthcare Corporation · Phase 4, Interventional, and Treatment

Why this study was terminated
Strategic business decision (not related to safety or efficacy concerns)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Dehydration with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Dehydration · United States.

Enrollment
49th of 74
20 · median 30
Started
2010
with 5 others
Phase 4
6 of 87
none open now
Registered
12th of 87
by date
Lead sponsor
3 of 87
Baxter Healthcare Corporation

Among the 87 studies in Dehydration with a site in United States, this one is the 49th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2010, is one of 6 in phase 4, and was the 12th registered.

Dehydration

201 studies on the registry are indexed under Dehydration; 28 are open to participants now.

Browse Dehydration studies →

Open to participants now

7 of the 87 studies in Dehydration with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Dehydration studies recruiting now, 7 (47%) set no upper age limit and 7 (47%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Dehydration with a site in United States, or all of them as a file.
02

Study summary

The purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (SC) infusion of Lactated Ringer's solution, preceded by recombinant human hyaluronidase (hylenex). The safety and tolerability of hylenex-augmented SC infusion of Lactated Ringer's solution fluid is also being evaluated.

03

Conditions studied

  • Dehydration

Browse trials for

Keywords

  • dehydration
  • fluid therapy
  • hyaluronoglucosaminidase
  • hyaluronidase
  • hypodermoclysis
  • clysis
  • subcutaneous hydration
  • subcutaneous rehydration
  • hyaluronan
  • rHuPH20
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18 to 60 years, inclusive.
  • 19.0 to 35.0 kg/m2
  • Intact normal skin without potentially obscuring tattoos, pigmentation, or lesions on the upper back in the area intended for infusion
  • Free from any abnormality on the basis of medical/medication history or physical examination
  • Vital signs and clinical laboratory parameters within normal range or, if outside normal range, deemed not clinically significant
  • Negative urine drug and alcohol screens.

Exclusion criteria

Exclusion Criteria:

  • Upper back pathology that could interfere with study outcome.
  • History of congestive heart failure, known coronary heart disease, active or recent pulmonary disease, or renal insufficiency.
  • Rales on lung auscultation.
  • Known allergy to hyaluronidase or any other ingredient in the formulation of hylenex recombinant
  • Treatment with furosemide, benzodiazepines, or phenytoin.
  • Pregnancy or breastfeeding.
  • Exposure to any experimental drug within 30 days prior to study admission, or previous participation in this study.
  • Any other reason which, in the investigator's opinion, would prevent the safe participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    24 ga catheter, dose flush, single-step rate scheme

    Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.

    Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

  • Experimental
    24 ga catheter, no dose flush, single-step rate scheme

    Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.

    Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

  • Experimental
    24 ga catheter, dose flush, up-titrated rate scheme

    Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.

    Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

  • Experimental
    24 ga catheter, no dose flush, up-titrated rate scheme

    Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.

    Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

  • Experimental
    25 ga needle, dose flush, single-step rate scheme

    Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.

    Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

  • Experimental
    25 ga needle, no dose flush, single-step rate scheme

    Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.

    Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

  • Experimental
    25 ga needle, dose flush, up-titrated rate scheme

    Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.

    Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

  • Experimental
    25 ga needle, no dose flush, up-titrated rate scheme

    Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.

    Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

Interventions

  • DrugSubcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

    Drug page: Hyaluronidase (human recombinant)

    Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

    Also known as: rHuPH20, LR solution

06

What researchers measure

Primary outcomes

  1. Maximum Measured In-line Fluid Pressure

    Maximum fluid pressure measured (15 sec period) in delivery line during subcutaneous fluid infusion at specified time point after start of infusion

    Time frame: each minute for the first 15 minutes of fluid infusion, every 5 minutes for the next 45 minutes of infusion, and every 15 minutes thereafter until the end of infusion

Secondary outcomes

  1. Number of Attempts Needed for Successful Subcutaneous Catheter/Needle Placement

    Time frame: end of catheter/needle placement

  2. Cumulative Fluid Volume Delivered

    Time frame: each minute for the first 15 minutes of fluid infusion, every 5 minutes for the next 45 minutes of infusion, and every 15 minutes thereafter until the end of infusion

  3. Technical Challenges Encountered During Fluid Infusion

    Observed challenges, including catheter kinking, catheter/needle dislodgement/pull-out, infusion pump alarm, other technical problems

    Time frame: at any occurence of a defined challenge or at end of infusion if no challenges occurred

07

Results

Posted Oct 18, 2011
Limitations and caveats
Due to small numbers of subjects in each treatment arm, no conclusions can be drawn on the influence of any of the individual potential pressure-affecting factors or the combinations of these factors on in-line fluid pressure.

Participant flow

Participant flow — Overall Study
Milestone24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate Scheme
Started23332223
Completed23332223
Not completed00000000

Outcome measures

PrimaryMaximum Measured In-line Fluid Pressure

Maximum fluid pressure measured (15 sec period) in delivery line during subcutaneous fluid infusion at specified time point after start of infusion

Time frame:
each minute for the first 15 minutes of fluid infusion, every 5 minutes for the next 45 minutes of infusion, and every 15 minutes thereafter until the end of infusion
Reported as:
Mean · psi
Maximum Measured In-line Fluid Pressure
psi24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate Scheme
1 min6.9 (2.6 to 11.1)3.0 (2.6 to 3.5)6.8 (3.1 to 10.6)5.0 (1.5 to 11.7)3.8 (3.7 to 3.8)2.8 (2.8 to 2.8)1.1 (1.0 to 1.2)3.0 (1.5 to 5.1)
2 min6.8 (2.8 to 10.8)2.4 (2.1 to 2.7)7.8 (3.3 to 12.3)5.9 (1.0 to 14.2)4.1 (3.8 to 4.4)3.1 (3.1 to 3.1)1.1 (0.9 to 1.4)2.4 (1.1 to 4.7)
3 min6.7 (2.8 to 10.6)2.1 (1.9 to 2.5)7.4 (3.5 to 11.2)6.1 (1.3 to 14.9)4.2 (4.1 to 4.4)3.2 (3.2 to 3.2)1.2 (1.1 to 1.3)2.5 (1.0 to 4.9)
4 min6.6 (2.8 to 10.4)2.1 (1.8 to 2.5)7.3 (3.7 to 11.0)6.0 (1.0 to 15.9)4.3 (4.3 to 4.3)3.2 (3.2 to 3.2)1.0 (1.0 to 1.1)2.8 (1.6 to 4.7)
5 min6.1 (2.7 to 9.5)2.6 (1.8 to 4.1)9.1 (7.7 to 10.6)5.7 (1.0 to 15.1)4.4 (4.3 to 4.4)3.2 (3.2 to 3.2)1.1 (1.1 to 1.1)2.5 (1.1 to 4.9)
6 min6.2 (2.8 to 9.6)3.3 (1.8 to 6.0)8.0 (4.9 to 11.1)7.1 (1.4 to 18.4)4.1 (4.0 to 4.2)3.2 (3.2 to 3.2)2.2 (2.1 to 2.2)2.4 (2.2 to 2.5)
7 min6.2 (2.8 to 9.7)3.2 (1.9 to 5.7)8.8 (3.4 to 14.1)7.1 (1.6 to 17.8)4.1 (4.1 to 4.2)3.2 (3.2 to 3.2)2.1 (2.1 to 2.2)3.8 (2.2 to 6.9)
8 min6.4 (2.8 to 10.1)3.6 (2.0 to 5.9)9.0 (3.7 to 14.4)7.3 (2.8 to 16.1)4.2 (4.1 to 4.3)3.2 (3.2 to 3.2)2.1 (2.1 to 2.2)4.6 (2.1 to 7.6)
9 min6.5 (2.8 to 10.2)3.8 (2.0 to 6.8)8.2 (2.9 to 13.5)7.0 (2.5 to 14.5)4.2 (4.2 to 4.2)3.2 (3.2 to 3.2)2.2 (2.1 to 2.3)4.1 (2.1 to 7.9)
10 min6.5 (2.8 to 10.2)3.9 (1.9 to 6.7)7.7 (2.9 to 12.5)6.2 (2.4 to 12.6)4.1 (4.1 to 4.2)3.2 (3.2 to 3.2)2.2 (2.1 to 2.3)3.9 (2.1 to 7.4)
11 min6.5 (2.7 to 10.3)3.7 (2.0 to 6.5)11.9 (5.5 to 18.2)7.6 (2.7 to 14.5)4.1 (4.0 to 4.2)3.2 (3.2 to 3.2)4.0 (3.9 to 4.0)6.4 (2.1 to 12.8)
12 min6.7 (2.7 to 10.6)4.2 (1.6 to 8.9)13.6 (4.3 to 22.9)10.3 (2.2 to 21.2)4.1 (4.1 to 4.2)3.2 (3.2 to 3.2)3.8 (3.7 to 3.9)7.4 (2.1 to 13.0)
13 min6.7 (2.7 to 10.7)3.6 (1.7 to 7.2)7.7 (3.1 to 12.2)10.5 (2.3 to 18.8)4.1 (4.0 to 4.2)3.2 (3.2 to 3.2)3.9 (3.8 to 4.0)7.0 (3.8 to 12.8)
14 min6.6 (2.7 to 10.5)3.0 (1.7 to 5.2)3.5 (2.6 to 4.4)17.7 (2.1 to 34.2)4.1 (4.0 to 4.2)3.3 (3.3 to 3.3)3.6 (3.4 to 3.9)6.9 (3.8 to 11.4)
15 min7.3 (3.5 to 11.0)4.0 (2.0 to 5.8)3.4 (2.6 to 4.2)15.8 (2.1 to 34.1)4.1 (4.1 to 4.2)3.2 (3.2 to 3.2)3.7 (3.5 to 3.9)6.5 (3.8 to 11.8)
20 min7.3 (3.1 to 11.5)2.2 (1.7 to 3.0)3.3 (2.7 to 3.9)11.9 (1.8 to 26.3)4.1 (4.0 to 4.3)3.2 (3.2 to 3.2)3.6 (3.5 to 3.7)6.2 (3.8 to 10.9)
25 min6.8 (3.1 to 10.4)2.4 (2.2 to 2.9)3.0 (2.0 to 4.1)8.7 (1.7 to 21.3)4.8 (4.3 to 5.4)3.2 (3.2 to 3.2)3.7 (3.7 to 3.8)6.1 (3.6 to 10.1)
30 min5.8 (3.3 to 8.3)2.2 (1.8 to 2.8)8.4 (2.1 to 14.8)8.6 (1.7 to 21.2)4.8 (4.8 to 4.9)3.2 (3.2 to 3.2)3.8 (3.5 to 4.0)5.8 (3.6 to 9.8)
35 min6.5 (3.3 to 9.8)2.7 (1.8 to 4.0)2.9 (2.0 to 3.9)10.9 (2.3 to 19.5)4.5 (4.5 to 4.5)3.3 (3.3 to 3.3)4.2 (3.4 to 5.1)6.4 (3.6 to 12.0)
40 min7.0 (3.2 to 10.9)2.2 (2.1 to 2.3)2.9 (2.0 to 3.8)11.5 (2.1 to 20.8)4.6 (4.5 to 4.6)3.2 (3.2 to 3.2)3.4 (3.4 to 3.4)5.9 (3.6 to 10.6)
45 min6.6 (2.8 to 10.4)2.3 (2.0 to 2.6)2.9 (2.0 to 3.9)7.4 (1.7 to 18.6)4.3 (4.1 to 4.6)3.2 (3.2 to 3.2)3.4 (3.3 to 3.5)5.8 (3.6 to 10.0)
50 min6.4 (2.7 to 10.0)2.2 (1.8 to 2.6)3.0 (1.9 to 4.1)7.8 (1.6 to 19.8)4.5 (4.5 to 4.5)3.3 (3.3 to 3.3)3.4 (3.3 to 3.5)5.8 (3.5 to 10.1)
55 min5.3 (2.8 to 7.9)2.4 (2.2 to 2.6)2.9 (1.9 to 3.8)7.9 (2.1 to 19.0)4.4 (4.3 to 4.5)3.2 (3.2 to 3.2)3.4 (3.2 to 3.5)6.0 (3.5 to 10.9)
60 min5.3 (2.9 to 7.7)3.1 (1.9 to 4.3)2.9 (2.0 to 3.8)7.7 (1.5 to 19.3)3.7 (3.6 to 3.8)3.2 (3.2 to 3.2)3.4 (3.3 to 3.4)6.5 (3.5 to 12.2)
75 min4.6 (2.6 to 6.7)2.6 (2.3 to 3.2)2.3 (1.8 to 2.8)5.9 (1.5 to 14.2)3.6 (3.0 to 4.1)2.8 (2.8 to 2.8)2.6 (2.6 to 2.7)7.8 (2.8 to 16.1)
90 min4.1 (2.9 to 5.3)3.6 (2.4 to 4.5)2.1 (1.6 to 2.7)4.0 (1.3 to 8.9)3.5 (3.0 to 4.0)2.7 (2.7 to 2.7)2.7 (2.6 to 2.8)7.5 (2.7 to 16.7)
105 min5.0 (2.9 to 7.1)2.7 (2.1 to 3.2)2.2 (1.7 to 2.7)4.5 (1.2 to 10.5)4.0 (3.1 to 4.9)2.7 (2.7 to 2.7)2.6 (2.6 to 2.6)6.3 (2.7 to 13.0)
120 min3.4 (2.7 to 4.1)2.6 (1.9 to 3.6)2.5 (1.5 to 3.4)5.2 (1.2 to 12.6)4.3 (3.5 to 5.1)2.9 (2.9 to 2.9)2.8 (2.6 to 3.0)6.8 (2.7 to 14.3)
135 min4.0 (3.0 to 4.9)2.2 (2.1 to 2.3)2.6 (2.3 to 2.9)5.0 (1.2 to 12.1)3.8 (2.9 to 4.7)2.7 (2.7 to 2.7)2.6 (2.6 to 2.7)7.4 (2.7 to 16.5)
150 min2.9 (2.9 to 3.0)7.8 (2.3 to 18.4)2.0 (1.4 to 2.6)5.0 (1.2 to 12.2)3.7 (2.9 to 4.4)2.6 (2.6 to 2.6)2.6 (2.5 to 2.7)7.0 (2.8 to 13.4)
165 min3.1 (2.7 to 3.4)2.6 (2.1 to 3.7)2.6 (2.4 to 2.8)5.0 (1.1 to 12.0)4.6 (4.1 to 5.1)2.6 (2.6 to 2.6)2.6 (2.5 to 2.6)3.4 (2.6 to 4.1)
180 min3.1 (2.9 to 3.4)2.1 (1.8 to 2.4)2.1 (1.4 to 2.7)4.8 (1.2 to 11.5)3.3 (2.7 to 3.9)2.6 (2.6 to 2.6)2.6 (2.5 to 2.6)3.2 (2.7 to 3.5)
195 min3.8 (3.0 to 4.6)4.0 (1.8 to 8.3)2.5 (1.5 to 3.4)5.2 (1.1 to 12.8)3.8 (3.1 to 4.4)2.6 (2.6 to 2.6)2.6 (2.5 to 2.8)3.4 (2.7 to 4.5)
210 min3.6 (3.1 to 4.2)4.0 (1.8 to 7.0)2.2 (1.9 to 2.4)4.8 (1.2 to 11.7)3.9 (2.9 to 4.9)2.8 (2.8 to 2.8)2.6 (2.5 to 2.7)6.3 (2.7 to 8.6)
225 min3.4 (3.1 to 3.6)4.3 (1.7 to 9.1)1.9 (1.5 to 2.3)4.9 (1.1 to 12.0)3.1 (2.9 to 3.3)2.4 (2.4 to 2.4)2.6 (2.5 to 2.7)3.3 (2.7 to 4.0)
240 min3.2 (3.0 to 3.5)3.9 (1.7 to 8.0)2.9 (1.4 to 4.3)7.4 (1.2 to 10.9)3.4 (2.6 to 4.2)2.6 (2.6 to 2.6)2.5 (2.5 to 2.6)5.3 (2.6 to 9.3)
255 min3.1 (2.6 to 3.6)4.0 (1.6 to 8.7)8.5 (1.3 to 15.6)4.8 (1.1 to 11.8)3.8 (2.7 to 4.8)2.5 (2.5 to 2.5)2.9 (2.7 to 3.0)4.9 (2.7 to 9.1)
270 min3.3 (3.2 to 3.4)4.4 (1.7 to 9.4)8.8 (1.9 to 15.6)5.0 (1.5 to 11.9)3.5 (2.5 to 4.4)2.7 (2.7 to 2.7)2.5 (2.4 to 2.6)4.8 (2.6 to 8.8)
285 min2.9 (2.8 to 3.0)4.9 (2.0 to 10.7)1.9 (1.4 to 2.5)4.4 (1.2 to 10.4)2.8 (2.5 to 3.1)2.5 (2.5 to 2.5)2.6 (2.6 to 2.6)4.3 (2.7 to 7.6)
SecondaryNumber of Attempts Needed for Successful Subcutaneous Catheter/Needle Placement
Time frame:
end of catheter/needle placement
Reported as:
Number · Subjects
Number of Attempts Needed for Successful Subcutaneous Catheter/Needle Placement
Subjects24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate Scheme
1 attempt23222123
2 attempts00010000
SecondaryCumulative Fluid Volume Delivered
Time frame:
each minute for the first 15 minutes of fluid infusion, every 5 minutes for the next 45 minutes of infusion, and every 15 minutes thereafter until the end of infusion
Reported as:
Mean · mL
Cumulative Fluid Volume Delivered
mL24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate Scheme
5 min20.8 (20.7 to 20.8)21.4 (20.6 to 22.2)4.2 (4.2 to 4.2)3.8 (3.1 to 4.2)21.1 (21.1 to 21.1)20.7 (20.7 to 20.7)4.1 (4.1 to 4.1)4.1 (4.1 to 4.2)
10 min41.2 (41.2 to 41.2)41.3 (39.6 to 42.9)11.7 (11.4 to 11.9)11.5 (10.4 to 12.3)42.0 (41.9 to 42.1)41.2 (41.2 to 41.2)12.1 (12.0 to 12.1)11.9 (11.8 to 12.1)
60 min250 (249 to 250)249 (248 to 250)249 (248 to 249)240 (228 to 247)249 (247 to 250)249 (249 to 249)248 (247 to 248)246 (243 to 248)
120 min448 (447 to 449)450 (448 to 452)449 (447 to 451)447 (447 to 448)449 (448 to 450)447 (447 to 447)448 (446 to 449)446 (441 to 448)
180 min649 (647 to 650)650 (648 to 652)649 (647 to 651)647 (647 to 648)649 (648 to 650)647 (647 to 647)650 (649 to 650)646 (641 to 648)
240 min848 (847 to 849)850 (848 to 853)849 (847 to 851)848 (847 to 849)849 (848 to 850)847 (847 to 847)847 (845 to 848)846 (841 to 848)
285 min998 (995 to 1000)1000 (998 to 1002)999 (997 to 1000)997 (997 to 998)999 (998 to 1000)997 (997 to 997)997 (997 to 997)996 (991 to 998)
SecondaryTechnical Challenges Encountered During Fluid Infusion

Observed challenges, including catheter kinking, catheter/needle dislodgement/pull-out, infusion pump alarm, other technical problems

Time frame:
at any occurence of a defined challenge or at end of infusion if no challenges occurred
Reported as:
Number · participants
Technical Challenges Encountered During Fluid Infusion
participants24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate Scheme
Any Technical Challenge00020000
Catheter Kinking00010000
Occlusion Alarm00020000
Intervention Needed to Secure/Maintain Infusion00010000

Adverse events

Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
24 ga Catheter, Dose Flush, Single-step Rate Scheme—0/2 (0%)2/2 (100%)
24 ga Catheter, No Dose Flush, Single-step Rate Scheme—0/3 (0%)3/3 (100%)
24 ga Catheter, Dose Flush, Up-titrated Rate Scheme—0/3 (0%)3/3 (100%)
24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme—0/3 (0%)3/3 (100%)
25 ga Needle, Dose Flush, Single-step Rate Scheme—0/2 (0%)2/2 (100%)
25 ga Needle, No Dose Flush, Single-step Rate Scheme—0/2 (0%)2/2 (100%)
25 ga Needle, Dose Flush, Up-titrated Rate Scheme—0/2 (0%)2/2 (100%)
25 ga Needle, No Dose Flush, Up-titrated Rate Scheme—0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
Event24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate Scheme
Infusion site erythemaGeneral disorders2/23/33/33/32/22/22/22/2
Infusion site painGeneral disorders2/23/32/32/32/20/22/22/3
Infusion site rashGeneral disorders1/23/31/32/31/20/21/21/3
Infusion site swellingGeneral disorders1/22/32/32/31/22/21/22/3
Infusion site oedemaGeneral disorders1/22/31/31/31/20/21/21/3
Infusion site pruritusGeneral disorders1/20/30/31/31/20/21/20/3
DizzinessNervous system disorders0/20/30/30/30/20/21/21/3
Hot flushVascular disorders0/20/31/30/30/20/21/20/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate SchemeTotal
<=18 years000000000
Between 18 and 65 years2333222320
>=65 years000000000
Age Continuous
Age Continuous(years)24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate SchemeTotal
Mean45.9 (33.5 to 58.3)32.6 (25.4 to 36.7)39.6 (21.4 to 50.0)29.3 (19.9 to 46.4)35.4 (20.3 to 50.5)39.7 (37.0 to 42.4)28.2 (24.1 to 32.3)20.9 (19.9 to 21.9)33.3 (19.9 to 58.3)
Sex: Female, Male
Sex: Female, Male(Participants)24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate SchemeTotal
Female2221122012
Male011210038
Region of Enrollment
Region of Enrollment(participants)24 ga Catheter, Dose Flush, Single-step Rate Scheme24 ga Catheter, No Dose Flush, Single-step Rate Scheme24 ga Catheter, Dose Flush, Up-titrated Rate Scheme24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme25 ga Needle, Dose Flush, Single-step Rate Scheme25 ga Needle, No Dose Flush, Single-step Rate Scheme25 ga Needle, Dose Flush, Up-titrated Rate Scheme25 ga Needle, No Dose Flush, Up-titrated Rate SchemeTotal
United States2333222320
08

Study locations

1 site
  • Kendle International, Inc. Drug Study Unit
    Morgantown, West Virginia 26505, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2010
First posted
May 4, 2010
Start
May 2010
Primary completionActual
May 2010
CompletionActual
Jun 2010
Results first posted
Oct 18, 2011
Last update
Oct 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01116102
Responsible party
Sponsor
First posted
May 4, 2010
Start date
May 2010
Primary completion
May 2010
Completion
Jun 2010
Results posted
Oct 18, 2011
Last update
Oct 24, 2011

Study contacts

George Harb, MD, MPH
study director · Baxter Healthcare Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion